CN111218436B - 一种植酸酶突变体 - Google Patents

一种植酸酶突变体 Download PDF

Info

Publication number
CN111218436B
CN111218436B CN201811423428.1A CN201811423428A CN111218436B CN 111218436 B CN111218436 B CN 111218436B CN 201811423428 A CN201811423428 A CN 201811423428A CN 111218436 B CN111218436 B CN 111218436B
Authority
CN
China
Prior art keywords
leu
pro
ala
thr
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811423428.1A
Other languages
English (en)
Other versions
CN111218436A (zh
Inventor
吴秀秀
李玉强
刘扬
黄亦钧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weifang Kdn Biotech Co ltd
Qingdao Vland Biotech Group Co Ltd
Original Assignee
Weifang Kdn Biotech Co ltd
Qingdao Vland Biotech Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weifang Kdn Biotech Co ltd, Qingdao Vland Biotech Group Co Ltd filed Critical Weifang Kdn Biotech Co ltd
Priority to CN201811423428.1A priority Critical patent/CN111218436B/zh
Publication of CN111218436A publication Critical patent/CN111218436A/zh
Application granted granted Critical
Publication of CN111218436B publication Critical patent/CN111218436B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/02Thioester hydrolases (3.1.2)
    • C12Y301/02006Hydroxyacylglutathione hydrolase (3.1.2.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/030083-Phytase (3.1.3.8)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02EREDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00Technologies for the production of fuel of non-fossil origin
    • Y02E50/10Biofuels, e.g. bio-diesel

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明涉及生物技术领域,特别涉及一种植酸酶突变体、编码该植酸酶突变体的DNA分子、载体、宿主细胞。所述植酸酶突变体的最适作用pH值为5.5,且在中性pH条件下的耐受性得到显著提高,在pH6.0条件下,所述突变体的相对酶活达到72.80%‑79.25%,在pH6.5条件下,所述突变体的相对酶活仍能达到32.99%‑40.95%,取得了意料不到的技术效果,有利于植酸酶在水产饲料中的广泛应用。

Description

一种植酸酶突变体
技术领域
本发明涉及蛋白质工程改造技术领域,具体涉及一种植酸酶突变体及其应用。
背景技术
植酸,又名肌醇六磷酸或环己六醇磷酸酯,广泛存在于植物籽实中,是植物性饲料中磷元素的主要储存形式,但植酸磷不能被动物直接吸收利用,必须在消化道内先水解为无机磷酸盐。水产动物尤其是鱼类消化系统中缺乏内源性植酸酶,无法利用饲料中的植酸磷,大部分随粪便排出,造成严重的水环境污染,同时造成磷的浪费。而水产动物对饲料中磷的需要量又高于畜禽,特别是鲤科鱼类属无胃鱼,没有胃酸分泌,通常采用饲料中添加磷酸氢钙或磷酸二氢钙等方法来满足水产动物机体对磷的营养需求。同时,植酸通常与一些二价或三价阳离子,如Ca2+、Zn2+、Fe2+等形成不溶性盐类,阻碍肠道对矿物元素的吸收。在酸性或近中性环境中植酸还可以与蛋白质形成络合物,影响蛋白质的吸收利用,与一些蛋白消化酶类等结合,降低了其活性。因此植酸也被认定为抗营养物质,它不仅造成饲料原料的浪费,无形中增加了养殖成本,还导致水产动物粪便中含有大量的氮磷和矿物质离子化合物,严重污染水环境。
植酸酶广泛存在于动物、植物和微生物中,是一类能将植酸及其盐类催化水解成肌醇和磷酸的酶的总称,属磷酸单酯水解酶。植酸酶作为环保促生长型饲料添加剂,可提高水产动物饲料中磷的利用率,减少水产动物养殖中磷对水环境的污染和水产饲料中矿物质磷的添加量,同时能提高植物蛋白和植物饲料能量矿物质利用率,从而节约饲料资源,降低饲料成本,符合我国两型社会建设要求,其在水产健康养殖中具有广阔的应用前景。
酸性植酸酶适用于胃pH呈酸性的单胃动物以及少数鱼类如虹蹲等,但不适用于消化道为中性的淡水鲤科鱼类和畜禽消化道中呈中性的部位。而中性植酸酶可以应用于消化道无胃、肠道pH呈中性的淡水鲤科鱼类饲料,对提高鱼类的生产效益、品质及降低饲料中植酸磷对环境的污染有重要意义。此外,中性植酸酶还可在 pH值逐渐升高至中性的单胃畜禽动物肠道中起作用,延长植酸酶在整个动物胃肠道中的作用时间,提高其有效性。但目前现有的植酸酶产品在中性pH条件下的酶活水平普遍偏低,尚不能满足水产养殖的要求。
发明内容
本发明为解决现有技术问题,提供了一种植酸酶突变体,其在中性pH条件下的酶活水平得到显著提高,可广泛应用于水产养殖饲料领域。
本发明提供了一种植酸酶突变体,其具有(Ⅰ)或(Ⅱ)所示的氨基酸序列:
(Ⅰ)与植酸酶的氨基酸序列SEQ ID NO:1具有至少90%同源性的序列;
(Ⅱ)具有所述植酸酶的至少一个免疫表位,且所述植酸酶的氨基酸序列经修饰、取代、缺失或添加一个或几个氨基酸获得的氨基酸序列。
在本发明的一些实施例中,所述取代为取代1个、2个、3个、4个、5个或6个氨基酸。
在本发明的一些实施例中,植酸酶突变体的氨基酸序列与植酸酶的氨基酸序列具有至少95%同源性的序列。
在本发明的另一些实施例中,植酸酶突变体的氨基酸序列与植酸酶的氨基酸序列具有至少96%同源性的序列。
在本发明的另一些实施例中,植酸酶突变体的氨基酸序列与植酸酶的氨基酸序列具有至少97%同源性的序列。
在本发明的另一些实施例中,植酸酶突变体的氨基酸序列与植酸酶的氨基酸序列具有至少98%同源性的序列。
在本发明的另一些实施例中,植酸酶突变体的氨基酸序列与植酸酶的氨基酸序列具有至少99%同源性的序列。
在本发明的一些实施例中,所述修饰包括酰胺化、磷酸化、甲基化、乙酰化、泛素化、糖基化或羰基化。
在本发明的另一些实施例中,所述取代为第253位、第254位或第327位中的任意一个或两个或三个氨基酸被取代。
在本发明的另一些实施例中,所述取代为第253位氨基酸由Gln变为Val,第254位氨基酸由Phe变为Trp,第327位氨基酸由Thr变为Leu。
在本发明的另一些实施例中,所述取代还包括第211位、第225位或第266位中的任意一个或两个或三个氨基酸被取代。
在本发明的另一些实施例中,所述取代还包括第211位氨基酸由Val变为Trp,第225位氨基酸由Gln变为Tyr,第266位氨基酸由Ser变为Pro。
在本发明的另一些实施例中,植酸酶突变体具有如SEQ ID NO:3或SEQ ID NO:4或SEQ ID NO:5或SEQ ID NO:7或SEQ ID NO:8或SEQ ID NO:9或SEQ ID NO:10或SEQ ID NO:11或SEQ ID NO:12或SEQ ID NO:13所示的氨基酸序列。
本发明还提供了编码上述的植酸酶突变体的DNA分子。
本发明还提拱了具有上述DNA分子的重组表达载体。
本发明还提供了一种宿主细胞,包含上述重组表达载体。
在本发明的一些实施例中,所述宿主细胞为毕赤酵母(Pichia pastoris),木霉(Trichoderma sp.)或曲霉(Aspergillus sp.)。
与植酸酶PHY-M相比,本发明提供的植酸酶突变体最适作用pH值为5.5,普遍向中性条件偏移了0.5个单位,且在中性pH条件下的耐受性得到显著提高。在pH6.0条件下,所述植酸酶突变体的相对酶活达到72.80%-79.25%,提高了29.3%-36.0%;在pH6.5条件下,所述植酸酶突变体的相对酶活仍能达到32.99%-40.95%,而植酸酶PHY-M的相对酶活仅有10.95%,取得了意料不到的技术效果。
本发明提供的植酸酶突变体PHY4,PHY5,PHY6,PHY7,PHY8,PHY9和PHY10的耐热性均得到显著提高;90℃处理3min后,植酸酶的酶活残留率普遍提高了10%-60.81%,其中植酸酶突变体PHY10的耐热性最高,酶活残留率高达80.93%。所述植酸酶突变体可广泛应用于水产饲料领域,前景广阔。
具体实施方式
本发明公开了一种植酸酶突变体、编码该植酸酶突变体的DNA分子、载体、宿主细胞,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
本发明用到了遗传工程和分子生物学领域使用的常规技术和方法,例如MOLECULAR CLONING: A LABORATORY MANUAL, 3nd Ed. (Sambrook, 2001)和CURRENTPROTOCOLS IN MOLECULAR BIOLOGY (Ausubel, 2003)中所记载的方法。这些一般性参考文献提供了本领域技术人员已知的定义和方法。但是,本领域的技术人员可以在本发明所记载的技术方案的基础上,采用本领域其它常规的方法、实验方案和试剂,而不限于本发明具体实施例的限定。
本发明具体实施例所使用的实验材料和试剂如下:
菌株与载体:大肠杆菌DH5α、毕赤酵母GS115、载体pPIC9K、Amp、G418购自Invitrogen公司。
酶与试剂盒:PCR酶及连接酶购买自Takara公司,限制性内切酶购自Fermentas公司,质粒提取试剂盒及胶纯化回收试剂盒购自Omega公司,GeneMorph II随机诱变试剂盒购自北京博迈斯生物科技有限公司。
培养基配方:
大肠杆菌培养基(LB培养基):0.5%酵母提取物,1%蛋白胨,1% NaCl,pH7.0);
LB-AMP培养基:LB培养基加100 μg/mL氨苄青霉素;
酵母培养基(YPD培养基):1%酵母提取物,2%蛋白胨,2%葡萄糖;
酵母筛选培养基(MD培养基):2%葡萄糖,2%琼脂糖,1.34% YNB,4×10-5生物素;
BMGY培养基:2%蛋白胨,1%酵母提取物,100 mM磷酸钾缓冲液(pH6.0),1.34% YNB,4×10-5生物素,1%甘油;
BMMY培养基:2%蛋白胨,1%酵母提取物,100 mM磷酸钾缓冲液(pH6.0),1.34% YNB,4×10-5生物素,0.5%甲醇。
下面结合实施例对本发明进行详细的描述。
实施例1 耐受中性pH环境的植酸酶突变体筛选
1.1 突变体筛选
为了提高大肠杆菌来源的植酸酶 PHY-M (氨基酸序列为SEQ ID NO:1,其编码核苷酸序列为SEQ ID NO:2)在中性pH条件下的耐受性,申请人首先委托上海捷瑞生物工程有限公司将上述序列依照毕赤酵母的密码偏爱性进行优化合成,并且在合成序列5’和3’两端分别加上EcoRI和NotI两个酶切位点。
对上述合成的PHY-M基因进行蛋白结构分析,该蛋白有两个结构域:N端的134个氨基酸残基与C端的152个氨基酸残基共同组成结构域1,剩余中间124氨基酸残基组成结构域2,保守序列和活性中心均位于结构域1中,在不破坏蛋白二级结构与活性中心的前提下,进一步对位点进行突变。
设计PCR引物PHY-M-F1和PHY-M-R1:
PHY-M-F1:GCTGAATTC CAATCCGAGCCAGAGTTGAAGTTGG;
(下划线为限制性内切酶EcoRI识别位点);
PHY-M-R1:CTGGCGGCCGC TTACTAAAGGGAACAAGCTGGGATTC;
(下划线为限制性内切酶NotI识别位点)
以PHY-M基因为模板,以上述引物用GeneMorph II随机突变PCR试剂盒(Stratagene)进行PCR扩增,胶回收PCR产物,EcoRI、NotI进行酶切处理后与经同样酶切后的pET21a载体连接,转化至大肠杆菌BL21(DE3)中,涂布于LB+Amp平板,37℃倒置培养,待转化子出现后,用牙签逐个挑至96孔板,每个孔中加入150ul含有0.1mM IPTG的LB+Amp培养基,37℃ 220rpm培养6 h左右,离心弃上清,菌体用缓冲液重悬,反复冻融破壁,获得含有植酸酶的大肠杆菌细胞裂解液。
分别用pH5.5、pH6.0和pH6.5的0.1M乙酸-乙酸钠缓冲液稀释细胞裂解液,分别取出40ul稀释后的裂解液至三块新的96孔板,三块96孔板都加入相应不同pH的80ul底物,于37℃反应30min后加入80ul终止液(钒酸铵:钼酸铵:硝酸=1:1:2)测定生成的无机磷含量,不同的突变子在不同的pH缓冲液下的酶活水平不同。
最终,申请人筛选到既能显著提高植酸酶PHY-M在中性pH条件下的耐受性,又不会显著影响其酶活和其他酶学性质的突变位点及位点的组合:F254W单点突变,Q253V/F254W两点突变,Q253V/F254W/T327L三点突变。
将上述含F254W单点突变的植酸酶突变体命名为PHY1,其氨基酸序列如SEQ IDNO:3所示;
将上述含Q253V和F254W两点突变的植酸酶突变体命名为PHY2,其氨基酸序列如SEQ ID NO:4所示;
将上述含Q253V、F254W和T327L三点突变的植酸酶突变体命名为PHY3,其氨基酸序列如SEQ ID NO:5所示。
1.2突变体基因的合成和表达载体的构建
由上海捷瑞生物工程有限公司依照毕赤酵母的密码偏爱性分别优化合成PHY1,PHY2和PHY3突变体序列,并且在合成序列5’和3’两端分别加上EcoRI和NotI两个酶切位点。
将上述合成的3条基因序列分别进行EcoRI和NotI双酶切,然后与经同样酶切后的pPIC-9K载体16℃过夜连接,并转化大肠杆菌DH5a,涂布于LB+Amp平板,37℃倒置培养,待转化子出现后,菌落PCR(反应体系及程序同实施例1.1)验证阳性克隆子,经测序验证后最后获得了正确的重组表达质粒,3个重组表达质粒分别命名为pPIC9K-PHY1、pPIC9K-PHY2、pPIC9K-PHY3。
通过上述同样的方法得到PHY-M的重组表达质粒,命名为毕赤酵母pPIC9K-PHY-M。
1.3毕赤酵母工程菌株的构建
分别将表达质粒pPIC9K-PHY-M、pPIC9K-PHY1、pPIC9K-PHY2和pPIC9K-PHY3用SacI进行线性化,线性化片段纯化回收后通过电穿孔法分别转化毕赤酵母GS115,在MD平板上筛选得到毕赤酵母重组菌株GS115/pPIC9K-PHY-M、GS115/pPIC9K-PHY1、GS115/pPIC9K-PHY2和GS115/pPIC9K-PHY3,然后在含不同浓度遗传霉素的YPD平板(0.5mg/mL-8mg/mL)上筛选多拷贝的转化子。
将毕赤酵母重组菌株GS115/pPIC9K-PHY-M的一个转化子命名为毕赤酵母PHY-M(Pichia pastoris PHY-M),GS115/pPIC9K-PHY1的一个转化子命名为毕赤酵母PHY1(Pichia pastoris PHY1),重组菌株GS115/pPIC9K-PHY2的一个转化子命名为毕赤酵母PHY2(Pichia pastoris PHY2),重组菌株GS115/pPIC9K- PHY3的一个转化子命名为毕赤酵母PHY3(Pichia pastoris PHY3)。将毕赤酵母PHY-M、PHY1、PHY2和PHY3分别转接于BMGY培养基中,30℃、250rpm振荡培养1d;再转入BMMY培养基中,30℃、250rpm振荡培养;每天添加0.5%的甲醇,诱导表达4 d;9000rpm离心10min去除菌体,即得到分别含植酸酶突变体PHY-M、PHY1、PHY2和PHY3的发酵上清液。
(1)植酸酶酶活单位的定义
在温度为37℃、pH为5.0的条件下,每分钟从浓度为5.0mmol/L植酸钠中释放1μmol无机磷,即为一个植酸酶活性单位,以U表示。
(2)植酸酶酶活测定方法
取甲、乙两支25mL比色管,各加入1.8mL乙酸缓冲液(PH 5.0)、0.2mL样品反应液,混匀,37℃预热5min。在甲管中加入4mL底物溶液,乙管中加入4mL终止液,混匀,37℃反应30min,反应结束后甲管中加入4mL终止液,乙管中加入4mL底物溶液,混匀。静置10min,分别在415nm波长处测定吸光值。每种样品作3个平行,取吸光值的平均值,通过标准曲线用回归直线方程计算植酸酶活性。
酶活X=F×C/(m×30)
其中:X——酶活力单位,U/g(mL);
F——试样溶液反应前的总稀释倍数;
C——根据实际样液的吸光值由直线回归方程计算出的酶活性,U;
m——试样质量或体积,g/mL;
30——反应时间;
(3)检测结果
采用上述方法分别对毕赤酵母PHY-M、毕赤酵母PHY1、毕赤酵母PHY2和毕赤酵母PHY3的发酵上清液进行植酸酶酶活测定。结果显示,毕赤酵母PHY-M、毕赤酵母PHY1、毕赤酵母PHY2和毕赤酵母PHY3发酵上清液的酶活分别为223 U/mL,185U/mL,157 U/mL和123U/mL。
1.4最适作用pH值分析
分别用pH5.0、5.5、6.0、6.5、7.0的0.1M乙酸-乙酸钠缓冲液对上述毕赤酵母PHY-M、PHY1、PHY2和PHY3发酵上清液进行稀释,在37℃条件下分别测定其植酸酶酶活,以最高酶活力计100%,计算相对酶活,具体结果如表1所示。
表1 植酸酶突变体在不同pH条件下的相对酶活
Figure 480633DEST_PATH_IMAGE001
从表1的结果可以看出,植酸酶PHY-M的最适作用pH值为5.0,而本发明提供的植酸酶突变体PHY1、PHY2和PHY3的最适作用pH值为5.5,向中性条件偏移了0.5个单位。
在pH6.0条件下,本发明提供的植酸酶突变体PHY1、PHY2和PHY3的相对酶活分别达到72.80%、75.98%和79.25%,比植酸酶PHY-M分别提高29.3%、32.73%和36.0%;在pH6.5条件下,本发明提供的植酸酶突变体PHY1、PHY2和PHY3的相对酶活仍能分别达到32.99%、37.53%和40.95%,而植酸酶PHY-M的相对酶活仅有10.95%。
上述结果表明,与植酸酶PHY-M相比,本发明提供的植酸酶突变体PHY1、PHY2和PHY3在中性pH条件下的耐受性得到显著提高,其中以突变体PHY3的耐受性最强,取得了意料不到的技术效果。
实施例2 耐高温植酸酶突变体的筛选
2.1 突变体筛选
为了提高植酸酶突变体PHY3(其氨基酸序列为SEQ ID NO:5,其编码核苷酸序列为SEQ ID NO:6)的耐热性,申请人进一步通过定向进化技术对该酶进行了大量突变的筛选。
以PHY3基因为模板,利用实施例1中所述引物PHY-M-F1、PHY-M-R1,用GeneMorphII随机突变PCR试剂盒(Stratagene)进行PCR扩增,胶回收PCR产物,EcoRI、Not I进行酶切处理后与经同样酶切后的pET21a载体连接,转化至大肠杆菌BL21(DE3)中,涂布于LB+Amp平板,37℃倒置培养,待转化子出现后,用牙签逐个挑至96孔板,每个孔中加入150 ul含有0.1mM IPTG的LB+Amp培养基,37℃ 220 rpm培养6 h左右,离心弃上清,菌体用缓冲液重悬,反复冻融破壁,获得含有植酸酶的大肠杆菌细胞裂解液。
分别取出40ul裂解液至两块新的96孔板,其中一块板于80℃处理10min后,两块96孔板都加入80ul底物,于37℃反应30min后加入80ul终止液(钒酸铵:钼酸铵:硝酸=1:1:2)测定生成的无机磷含量,不同的突变子经过高温处理后,其植酸酶的残留酶活不同。
最终,申请人筛选到既能显著提高植酸酶突变体PHY3的耐热性,又不会显著影响其酶活及原有酶学性质的突变位点及组合:V211W,Q225Y,S266P,V211W/Q225Y,V211W/S266P,Q225Y/S266P,V211W/Q225Y/S266P。
将上述含V211W单点突变的植酸酶突变体命名为PHY4,其氨基酸序列如SEQ IDNO:7所示;
将上述含Q225Y单点突变的植酸酶突变体命名为PHY5,其氨基酸序列如SEQ IDNO:8所示;
将上述含S266P单点突变的植酸酶突变体命名为PHY6,其氨基酸序列如SEQ IDNO:9所示;
将上述含V211W和Q225Y两点突变的植酸酶突变体命名为PHY7,其氨基酸序列如SEQ ID NO:10所示;
将上述含V211W和S266P两点突变的植酸酶突变体命名为PHY8,其氨基酸序列如SEQ ID NO:11所示;
将上述含Q225Y和S266P两点突变的植酸酶突变体命名为PHY9,其氨基酸序列如SEQ ID NO:12所示;
将上述含V211W,Q225Y和S266P三点突变的植酸酶突变体命名为PHY10,其氨基酸序列如SEQ ID NO:13所示。
2.2 突变体基因合成与工程菌株构建
由上海捷瑞生物工程有限公司依照毕赤酵母的密码偏爱性分别优化合成突变体PHY4,PHY5,PHY6,PHY7,PHY8,PHY9和PHY10的基因序列,并且在合成序列5’和3’两端分别加上EcoRI和NotI两个酶切位点。
采用实施例1中所述方法,分别构建得到重组表达植酸酶突变体PHY4,PHY5,PHY6,PHY7,PHY8,PHY9和PHY10的毕赤酵母工程菌株,依次命名为毕赤酵母PHY4,PHY5,PHY6,PHY7,PHY8,PHY9和PHY10。采用实施例1中所述植酸酶酶活测定方法对上述毕赤酵母工程菌株发酵上清液进行酶活测定,具体结果见表2。
表2 毕赤酵母工程菌株发酵上清液酶活
Figure 804298DEST_PATH_IMAGE002
2.3 耐热性分析
用预热10min、pH5.0 的0.25M乙酸钠缓冲液分别将上述毕赤酵母PHY4、PHY5、PHY6、PHY7、PHY8、PHY9和PHY10的发酵上清液稀释10倍,混合均匀;90℃处理3min后,分别取样并冷却至室温,然后测定稀释后的植酸酶酶活,以未高温处理样品的酶活计100%,计算酶活残留率。同时以毕赤酵母PHY3发酵上清液作为对照。结果如表3所示。
酶活残留率(%)=(未高温处理样品的酶活-高温处理后样品的酶活)/未高温处理样品的酶活×100%。
表3 植酸酶突变体耐热性分析
Figure 662664DEST_PATH_IMAGE003
从表3的数据可以看出,与植酸酶PHY3相比,本发明提供的植酸酶突变体PHY4,PHY5,PHY6,PHY7,PHY8,PHY9和PHY10的耐热性均得到显著提高;90℃处理3min后,植酸酶的酶活残留率普遍提高了10%-60.81%,其中植酸酶突变体PHY10的耐热性最高,酶活残留率高达80.93%,取得了意料不到的技术效果。申请人进一步参照实施例1.4所述方法对毕赤酵母PHY4、PHY5、PHY6、PHY7、PHY8、PHY9和PHY10的发酵上清液进行最适作用pH分析。结果显示所述7株工程菌重组表达的植酸酶突变体PHY4,PHY5,PHY6,PHY7,PHY8,PHY9和PHY10的最适作用pH均为5.5,且在pH6.0的条件残留酶活均为80%左右,在pH6.5条件下残留酶活均为40%左右,与植酸酶PHY3基本相当。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 青岛蔚蓝生物集团有限公司
潍坊康地恩生物科技有限公司
<120> 一种植酸酶突变体
<160> 13
<170> SIPO Sequence Listing 1.0
<210> 1
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Val Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Gln Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Gln Phe Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Ser Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Thr Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 2
<211> 1233
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
cagtcagaac cagagttgaa gttggagtca gtcgtcatcg ttagtagaca tggagttaga 60
gcccctacaa agtttaccca gcttatgcaa gatgttaccc cagacgcttg gccaacttgg 120
cctgtcaagt tgggagaact tactcctaga ggtggagagt tgattgccta ccttggtcat 180
tattggagac aaagattggt tgcagatgaa ttgcttccaa agtgtggttg ccctcaacca 240
ggacaggttg caattatcgc tgatgttgat gaaagaacta gaaaaacagg agaggctttt 300
gctgccggat tggccccaga ttgtgcaatc actgttcatc accaagccga tacatcttcc 360
ccagaccctt tgttcaaccc tcttaagaca ggagtctgtc agttggatgt tgccaatgtc 420
accagagcaa ttttggaaag agctggtgga agtatcgccg actttactgg tcactaccaa 480
ccagctttca gagaattgga gagagttctt aactttccac agtccccatt gtgtcttaag 540
agagaaaagc aagatgagcc atgcagtttg actcaggctc ttccttctga gttgaaagtt 600
tccgccgaca acgtctcatt gaccggagct gtttctcttg cctccatgtt gactgaaatt 660
ttcttgcttc aacaggctca gggtatgcca gagcctggtt ggggaagaat caccgatagt 720
catcagtgga acactttgct ttctttgcac aatgctcaat tcgacttgct tcagagaact 780
ccagaagttg caagatccag agctacacct ttgcttgatc ttattaagac cgcattgact 840
ccacatccac ctcaaaaaca ggcttatgga gttacattgc ctacctctgt cttgttcatc 900
gctggtcacg acactaactt ggcaaatctt ggtggagctt tggagcttaa ctggacattg 960
ccaggtcaac ctgataatac cccacctggt ggagaattgg tttttgagag atggagaaga 1020
ttgtcagaca atagtcaatg gattcaggtt tccttggtct tccaaacttt gcaacagatg 1080
agagataaga caccattgtc acttaacacc ccacctggtg aagtcaaatt gacacttcct 1140
ggatgtgaag agagaaatgc acaaggaatg tgcagtcttg ctggtttcac ccaaatcgtc 1200
aatgaggcta gaatccctgc ttgttccttg taa 1233
<210> 3
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Val Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Gln Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Gln Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Ser Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Thr Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 4
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Val Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Gln Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Val Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Ser Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Thr Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 5
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Val Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Gln Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Val Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Ser Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Leu Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 6
<211> 1233
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
cagtcagaac cagagttgaa gttggagtca gtcgtcatcg ttagtagaca tggagttaga 60
gcccctacaa agtttaccca gcttatgcaa gatgttaccc cagacgcttg gccaacttgg 120
cctgtcaagt tgggagaact tactcctaga ggtggagagt tgattgccta ccttggtcat 180
tattggagac aaagattggt tgcagatgaa ttgcttccaa agtgtggttg ccctcaacca 240
ggacaggttg caattatcgc tgatgttgat gaaagaacta gaaaaacagg agaggctttt 300
gctgccggat tggccccaga ttgtgcaatc actgttcatc accaagccga tacatcttcc 360
ccagaccctt tgttcaaccc tcttaagaca ggagtctgtc agttggatgt tgccaatgtc 420
accagagcaa ttttggaaag agctggtgga agtatcgccg actttactgg tcactaccaa 480
ccagctttca gagaattgga gagagttctt aactttccac agtccccatt gtgtcttaag 540
agagaaaagc aagatgagcc atgcagtttg actcaggctc ttccttctga gttgaaagtt 600
tccgccgaca acgtctcatt gaccggagct gtttctcttg cctccatgtt gactgaaatt 660
ttcttgcttc aacaggctca gggtatgcca gagcctggtt ggggaagaat caccgatagt 720
catcagtgga acactttgct ttctttgcac aatgctgtct gggacttgct tcagagaact 780
ccagaagttg caagatccag agctacacct ttgcttgatc ttattaagac cgcattgact 840
ccacatccac ctcaaaaaca ggcttatgga gttacattgc ctacctctgt cttgttcatc 900
gctggtcacg acactaactt ggcaaatctt ggtggagctt tggagcttaa ctggacattg 960
ccaggtcaac ctgataattt gccacctggt ggagaattgg tttttgagag atggagaaga 1020
ttgtcagaca atagtcaatg gattcaggtt tccttggtct tccaaacttt gcaacagatg 1080
agagataaga caccattgtc acttaacacc ccacctggtg aagtcaaatt gacacttcct 1140
ggatgtgaag agagaaatgc acaaggaatg tgcagtcttg ctggtttcac ccaaatcgtc 1200
aatgaggcta gaatccctgc ttgttccttg taa 1233
<210> 7
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Trp Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Gln Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Val Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Ser Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Leu Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 8
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Val Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Tyr Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Val Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Ser Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Leu Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 9
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Val Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Gln Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Val Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Pro Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Leu Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 10
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Trp Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Tyr Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Val Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Ser Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Leu Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 11
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Trp Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Gln Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Val Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Pro Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Leu Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 12
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Val Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Tyr Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Val Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Pro Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Leu Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410
<210> 13
<211> 410
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser Val Val Ile Val Ser Arg
1 5 10 15
His Gly Val Arg Ala Pro Thr Lys Phe Thr Gln Leu Met Gln Asp Val
20 25 30
Thr Pro Asp Ala Trp Pro Thr Trp Pro Val Lys Leu Gly Glu Leu Thr
35 40 45
Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu Gly His Tyr Trp Arg Gln
50 55 60
Arg Leu Val Ala Asp Glu Leu Leu Pro Lys Cys Gly Cys Pro Gln Pro
65 70 75 80
Gly Gln Val Ala Ile Ile Ala Asp Val Asp Glu Arg Thr Arg Lys Thr
85 90 95
Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro Asp Cys Ala Ile Thr Val
100 105 110
His His Gln Ala Asp Thr Ser Ser Pro Asp Pro Leu Phe Asn Pro Leu
115 120 125
Lys Thr Gly Val Cys Gln Leu Asp Val Ala Asn Val Thr Arg Ala Ile
130 135 140
Leu Glu Arg Ala Gly Gly Ser Ile Ala Asp Phe Thr Gly His Tyr Gln
145 150 155 160
Pro Ala Phe Arg Glu Leu Glu Arg Val Leu Asn Phe Pro Gln Ser Pro
165 170 175
Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu Pro Cys Ser Leu Thr Gln
180 185 190
Ala Leu Pro Ser Glu Leu Lys Val Ser Ala Asp Asn Val Ser Leu Thr
195 200 205
Gly Ala Trp Ser Leu Ala Ser Met Leu Thr Glu Ile Phe Leu Leu Gln
210 215 220
Tyr Ala Gln Gly Met Pro Glu Pro Gly Trp Gly Arg Ile Thr Asp Ser
225 230 235 240
His Gln Trp Asn Thr Leu Leu Ser Leu His Asn Ala Val Trp Asp Leu
245 250 255
Leu Gln Arg Thr Pro Glu Val Ala Arg Pro Arg Ala Thr Pro Leu Leu
260 265 270
Asp Leu Ile Lys Thr Ala Leu Thr Pro His Pro Pro Gln Lys Gln Ala
275 280 285
Tyr Gly Val Thr Leu Pro Thr Ser Val Leu Phe Ile Ala Gly His Asp
290 295 300
Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu Glu Leu Asn Trp Thr Leu
305 310 315 320
Pro Gly Gln Pro Asp Asn Leu Pro Pro Gly Gly Glu Leu Val Phe Glu
325 330 335
Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln Trp Ile Gln Val Ser Leu
340 345 350
Val Phe Gln Thr Leu Gln Gln Met Arg Asp Lys Thr Pro Leu Ser Leu
355 360 365
Asn Thr Pro Pro Gly Glu Val Lys Leu Thr Leu Pro Gly Cys Glu Glu
370 375 380
Arg Asn Ala Gln Gly Met Cys Ser Leu Ala Gly Phe Thr Gln Ile Val
385 390 395 400
Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu
405 410

Claims (5)

1.一种植酸酶突变体,其特征在于,所述突变体的氨基酸序列为SEQ ID NO:3或SEQ IDNO:4或SEQ ID NO:5或SEQ ID NO:7或SEQ ID NO:8或SEQ ID NO:9或SEQ ID NO:10或SEQID NO:11或SEQ ID NO:12或SEQ ID NO:13。
2.编码如权利要求1所述的植酸酶突变体的DNA分子。
3.具有如权利要求2所述DNA分子的重组表达载体。
4.一种宿主细胞,其特征在于,包含如权利要求3所述的重组表达载体。
5.如权利要求4所述的宿主细胞,其特征在于,所述的宿主细胞为毕赤酵母(Pichia pastoris),木霉(Trichoderma sp.)或曲霉(Aspergillus sp.)。
CN201811423428.1A 2018-11-27 2018-11-27 一种植酸酶突变体 Active CN111218436B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811423428.1A CN111218436B (zh) 2018-11-27 2018-11-27 一种植酸酶突变体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811423428.1A CN111218436B (zh) 2018-11-27 2018-11-27 一种植酸酶突变体

Publications (2)

Publication Number Publication Date
CN111218436A CN111218436A (zh) 2020-06-02
CN111218436B true CN111218436B (zh) 2022-08-30

Family

ID=70830351

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811423428.1A Active CN111218436B (zh) 2018-11-27 2018-11-27 一种植酸酶突变体

Country Status (1)

Country Link
CN (1) CN111218436B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114807093B (zh) * 2022-06-22 2022-09-27 中国农业科学院北京畜牧兽医研究所 一种通过c端添加融合肽段提高木聚糖酶和植酸酶热稳定性的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036607A1 (en) * 1999-11-18 2001-05-25 Cornell Research Foundation, Inc. Site-directed mutagenesis of escherichia coli phytase
CN102131924A (zh) * 2008-06-06 2011-07-20 丹尼斯科美国公司 来自枯草芽孢杆菌的变体α-淀粉酶及其使用方法
CN105624131A (zh) * 2014-11-21 2016-06-01 青岛蔚蓝生物集团有限公司 植酸酶突变体
CN107236717A (zh) * 2016-03-28 2017-10-10 青岛蔚蓝生物集团有限公司 植酸酶突变体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004050410A1 (de) * 2004-10-15 2006-06-08 Ab Enzymes Gmbh Polypeptid mit Phytaseaktivität und dieses codierende Nucleotidsequenz
CN102906255A (zh) * 2010-03-26 2013-01-30 诺维信公司 热稳定性肌醇六磷酸酶变体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036607A1 (en) * 1999-11-18 2001-05-25 Cornell Research Foundation, Inc. Site-directed mutagenesis of escherichia coli phytase
CN102131924A (zh) * 2008-06-06 2011-07-20 丹尼斯科美国公司 来自枯草芽孢杆菌的变体α-淀粉酶及其使用方法
CN105624131A (zh) * 2014-11-21 2016-06-01 青岛蔚蓝生物集团有限公司 植酸酶突变体
CN107236717A (zh) * 2016-03-28 2017-10-10 青岛蔚蓝生物集团有限公司 植酸酶突变体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
phytase, partial [synthetic construct];AFP19812.1;《GenBank》;20120805;ORIGIN部分 *

Also Published As

Publication number Publication date
CN111218436A (zh) 2020-06-02

Similar Documents

Publication Publication Date Title
US11739336B2 (en) Phytase mutants
EP3438253B1 (en) Phytase mutant
CN109402091B (zh) 木聚糖酶突变体
CN104450643B (zh) 植酸酶突变体及其应用
CN110029120B (zh) 一种植酸酶高产菌株及其应用
CN110577946B (zh) 酶活性和耐热性提高的β-甘露聚糖酶突变体及其编码基因和应用
CN110607291B (zh) 耐热木聚糖酶突变体
WO2021233361A1 (zh) 植酸酶突变体
WO2020168943A1 (zh) 植酸酶突变体
CN110607292A (zh) 一种高比活木聚糖酶突变体
CN111218436B (zh) 一种植酸酶突变体
CN104911160A (zh) 一种中性植酸酶突变体及其应用
CN109207446B (zh) 葡萄糖氧化酶突变体
CN114317488B (zh) 一种比活力提高的植酸酶突变体
CN109694858B (zh) 一种植酸酶突变体
CN107988177B (zh) 葡萄糖氧化酶突变体
CN115094050B (zh) 一种中性植酸酶突变体及其应用
WO2020063267A1 (zh) 植酸酶突变体
CN115094049B (zh) 耐高温中性植酸酶突变体
CN116121222A (zh) 一种中性植酸酶突变体及其应用
CN113717959B (zh) 植酸酶突变体
CN111635895B (zh) 植酸酶突变体
CN113528487A (zh) 一种通过迭代饱和突变提高木聚糖酶热稳定性的方法
CN114736886A (zh) 植酸酶突变体及其制备方法
CN113528486A (zh) 一种引入二硫键提高木聚糖酶热稳定性的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant